Elevated Total Homocysteine Levels in Acute Ischemic Stroke Are Associated with Long-Term Mortality

Stroke

Volumn 46, Issue 9, 2015, Pages 2419-2425

  Shi, Zhihong ^a,b   Guan, Yalin ^a,b   Huo, Ya Ruth ^c   Liu, Shuling ^a,b   Zhang, Meilin ^d   Lu, Hui ^a,b   Yue, Wei ^a,b   Wang, Jinhuan ^a   Ji, Yong ^a,b  

^a TIANJIN HUANHU HOSPITAL   (China)

^b Tianjin Huanhu Hospital   (China)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

acute ischemic stroke; atherosclerosis; homocysteine; long term mortality; stroke

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; AUTOANALYZER; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COLORIMETRY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRINKING BEHAVIOR; ENDOCRINE FUNCTION TEST; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SMOKING; STROKE PATIENT; AGED; BLOOD; CEREBROVASCULAR ACCIDENT; FOLLOW UP; MORTALITY; PROGNOSIS; RECURRENT DISEASE;

AGED; BRAIN ISCHEMIA; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; STROKE;

EID: 84940396818     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.009136     Document Type: Article

References (38)

1. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation. 2011;124:314-323. doi: 10.1161/CIRCULATIONAHA.111.018820.
2. Moran A, Gu D, Zhao D, Coxson P, Wang YC, Chen CS, et al. Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes. 2010;3:243-252. doi: 10.1161/CIRCOUTCOMES.109.910711.
3. Lai SM, Alter M, Friday G, Sobel E. A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke. 1994;25:958-962.
4. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365:224-232. doi: 10.1016/S0140-6736(05)17742-3.
5. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J. 2002; 325: 1202-1206.
6. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002; 288, 2015-2022.
7. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med. 1999;131:352-355.
8. Iso H, Moriyama Y, Sato S, Kitamura A, Tanigawa T, Yamagishi K, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation. 2004;109:2766-2772. doi: 10.1161/01. CIR.0000131942.77635.2D.
9. Sacco RL, Anand K, Lee HS, Boden-Albala B, Stabler S, Allen R, et al. Homocysteine and the risk of ischemic stroke in a triethnic cohort: the NOrthern MAnhattan Study. Stroke. 2004;35:2263-2269. doi: 10.1161/01.STR.0000142374.33919.92.
10. Cui R, Moriyama Y, Koike KA, Date C, Kikuchi S, Tamakoshi A, et al; JACC Study group. Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: The JACC study. Atherosclerosis. 2008;198:412-418. doi: 10.1016/j. atherosclerosis.2007.09.029.
11. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050. doi: 10.1056/NEJM199804093381507.
12. Mudd SH, Finkelstein JD, Refsum H, Ueland PM, Malinow MR, Lentz SR et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 2000; 20:1704-1706.
13. Spence JD. B vitamin therapy for homocysteine: renal function and vitamin B12 determine cardiovascular outcomes. Clin Chem Lab Med 2013; 51:633-637.
14. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575. doi: 10.1001/jama.291.5.565.
15. Bostom AG, Selhub J, Jacques PF, Rosenberg IH. Power Shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. Ann Intern Med. 2001;135:133-137.
16. Boysen G, Brander T, Christensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke. Stroke. 2003;34:1258-1261. doi: 10.1161/01.STR.0000069017.78624.37.
17. Del Ser T, Barba R, Herranz AS, Seijas V, López-Manglano C, Domingo J, et al. Hyperhomocyst(e)inemia is a risk factor of secondary vascular events in stroke patients. Cerebrovasc Dis. 2001;12:91-98. doi: 47687.
18. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
19. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation. 1997;95:1683-1685.
20. American Diabetes Association. Diagnosis and classification of diabetesmellitus. Diabetes Care. 2005; 28(suppl 1):S37-S42.
21. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-1992. doi: 10.1097/01. hjh.0000084751.37215.d2.
22. Zhang W, Sun K, Chen J, Liao Y, Qin Q, Ma A, et al. High plasma homocysteine levels contribute to the risk of stroke recurrence and allcause mortality in a large prospective stroke population. Clin Sci (Lond). 2010;118:187-194. doi: 10.1042/CS20090142.
23. Naess H, Nyland H, Idicula T, Waje-Andreassen U. C-reactive protein and homocysteine predict long-term mortality in young ischemic stroke patients. J Stroke Cerebrovasc Dis. 2013;22:e435-e440. doi: 10.1016/j. jstrokecerebrovasdis.2013.04.031.
24. Campbell N, Brant R, Stalts H, Stone J, Mahallati H. Fluctuations in blood lipid levels during furosemide therapy: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med. 1998;158:1461-1463.
25. Campbell NR, Wickert W, Magner P, Shumak SL. Dehydration during fasting increases serum lipids and lipoproteins. Clin Invest Med. 1994;17:570-576.
26. Parnetti L, Caso V, Santucci A, Corea F, Lanari A, Floridi A, et al. Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. Neurol Sci. 2004;25:13-17. doi: 10.1007/s10072-004-0219-5.
27. Tay SY, Ampil ER, Chen CP, Auchus AP. The relationship between homocysteine, cognition and stroke subtypes in acute stroke. J Neurol Sci. 2006;250:58-61. doi: 10.1016/j.jns.2006.06.028.
28. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308-318. doi: 10.1172/JCI116187.
29. Okamura T, Kitamura A, Moriyama Y, Imano H, Sato S, Terao A, et al. Plasma level of homocysteine is correlated to extracranial carotidartery atherosclerosis in non-hypertensive Japanese. J Cardiovasc Risk. 1999;6:371-377.
30. Nygård O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 1995;274:1526-1533.
31. Dardik R, Varon D, Tamarin I, Zivelin A, Salomon O, Shenkman B, et al. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost. 2000;83:338-344.
32. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:6369-6373.
33. Schreiner PJ, Wu KK, Malinow MR, Stinson VL, Szklo M, Nieto FJ, et al. Hyperhomocyst(e)inemia and hemostatic factors: the atherosclerosis risk in communities study. Ann Epidemiol. 2002;12:228-236.
34. Perini F, Galloni E, Bolgan I, Bader G, Ruffini R, Arzenton E, et al. Elevated plasma homocysteine in acute stroke was not associated with severity and outcome: stronger association with small artery disease. Neurol Sci. 2005;26:310-318. doi: 10.1007/s10072-005-0505-7.
35. Ciccone MM, K Sharma R, Scicchitano P, Cortese F, Salerno C, Berchialla P, et al. Dolichocarotids: echo-color Doppler evaluation and clinical role. J Atheroscler Thromb. 2014; 21:56-63.
36. Ciccone MM, Scicchitano P, Palumbo V, Cortese F, Valecce R, Dentamaro I, et al. Dolichocarotids and dilated cardiomyopathy: is there a relationship? Int J Cardiol. 2012;158:123-125. doi: 10.1016/j. ijcard.2012.04.052.
37. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489-1494.
38. Scicchitano P, Cortese F, Ricci G, Carbonara S, Moncelli M, Iacoviello M, et al. Ivabradine, coronary artery disease, and heart failure: beyond rhythm control. Drug Des Devel Ther. 2014;8:689-700. doi: 10.2147/DDDT.S60591.